LLY

1,062.5

+2.21%↑

JNJ

208.38

-0.82%↓

ABBV

224.35

-0.35%↓

UNH

327.5

-1.41%↓

AZN

90.72

+0.41%↑

LLY

1,062.5

+2.21%↑

JNJ

208.38

-0.82%↓

ABBV

224.35

-0.35%↓

UNH

327.5

-1.41%↓

AZN

90.72

+0.41%↑

LLY

1,062.5

+2.21%↑

JNJ

208.38

-0.82%↓

ABBV

224.35

-0.35%↓

UNH

327.5

-1.41%↓

AZN

90.72

+0.41%↑

LLY

1,062.5

+2.21%↑

JNJ

208.38

-0.82%↓

ABBV

224.35

-0.35%↓

UNH

327.5

-1.41%↓

AZN

90.72

+0.41%↑

LLY

1,062.5

+2.21%↑

JNJ

208.38

-0.82%↓

ABBV

224.35

-0.35%↓

UNH

327.5

-1.41%↓

AZN

90.72

+0.41%↑

Search

Celldex Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

25.42 -3.71

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

25.24

Max

26.66

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-10M

-67M

Pelnas, tenkantis vienai akcijai

-1.01

Pelno marža

-7,753.425

Darbuotojai

186

EBITDA

-3.2M

-66M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+104.91% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

295M

1.8B

Ankstesnė atidarymo kaina

29.13

Ankstesnė uždarymo kaina

25.42

Naujienos nuotaikos

By Acuity

50%

50%

159 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-17 23:50; UTC

Karštos akcijos

Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed

2025-12-17 23:20; UTC

Uždarbis

Correction to Micron Logs Sales Jump Article

2025-12-17 23:07; UTC

Uždarbis

Micron Logs Sales Jump, Sees Further Growth as AI Demand Outpaces Supply -- Update

2025-12-17 21:37; UTC

Uždarbis

Micron Technology 1Q Sales Jump 57%, Led By Memory Growth

2025-12-17 23:53; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Some Tailwinds -- Market Talk

2025-12-17 23:43; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

2025-12-17 23:06; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Transaction Expected to Be Closed in 2H of Calendar Year 2026

2025-12-17 23:05; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Currently No Plans of Issuing New Shares in Asahi

2025-12-17 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Funds to Be Provided Via Borrowings From Financial Institutions or Cash on Hand

2025-12-17 23:03; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Acquisition of 53.68% Stake in UDV (Kenya) is $646M on Equity Value Basis

2025-12-17 23:02; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Acquisition of 100% Stake in Diageo Kenya is $2.354B on Equity Value Basis

2025-12-17 22:59; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Deal Part of Strategy Under Medium- to Long-Term Management Policy

2025-12-17 22:57; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: To Indirectly Acquire 65.00% Stake in East African Breweries PLC

2025-12-17 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group: Stakes Acquired From Two Subsidiaries of Diageo Plc

2025-12-17 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Asahi Group Holdings: To Acquire 100% Stake in Diageo Kenya Ltd., 53.68% Stake in UVD (Kenya) Ltd.

2025-12-17 22:49; UTC

Rinkos pokalbiai

Sandfire Resources Production Pipeline Strength Questioned -- Market Talk

2025-12-17 21:58; UTC

Uždarbis

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

2025-12-17 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-12-17 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-17 21:46; UTC

Uždarbis

Salesforce and Other AI Stocks That Can Catch Up to the Pack -- Barrons.com

2025-12-17 21:20; UTC

Uždarbis

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

2025-12-17 21:10; UTC

Uždarbis

Micron Beats Earnings. The Stock Is Rising. -- Barrons.com

2025-12-17 21:05; UTC

Uždarbis

Micron Technology Anticipates Business Performance to Continue Strengthening Through FY26

2025-12-17 21:04; UTC

Uždarbis

Micron Technology: 2Q Outlook Reflects Substantial Records Across Rev, Gross Margin, EPS and Free Cash Flow >MU

2025-12-17 21:04; UTC

Uždarbis

Micron Technology Sees 2Q Oper Expenses $1.56B, Plus or Minus $20M >MU

2025-12-17 21:03; UTC

Uždarbis

Micron Technology Sees 2Q Adj EPS $8.42, Plus or Minus 20c >MU

2025-12-17 21:03; UTC

Uždarbis

Micron Technology Sees 2Q EPS $8.19, Plus or Minus 20c >MU

2025-12-17 21:03; UTC

Uždarbis

Micron Technology Sees 2Q Revenue $18.7B, Plus or Minus $400M >MU

2025-12-17 21:02; UTC

Uždarbis

Micron Technology 1Q Operating Cash Flow $8.41 B >MU

2025-12-17 21:01; UTC

Uždarbis

Micron Technology 1Q Rev $13.64B >MU

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

104.91% į viršų

12 mėnesių prognozė

Vidutinis 54.67 USD  104.91%

Aukščiausias 90 USD

Žemiausias 21 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

159 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat